NCCN VERSION 2 2015

171 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-96
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
399. Karlsson E, Lindström LS, Wilking U, et al. Discordance in
hormone receptor status in breast cancer during tumor progression
[abstract]. J Clin Oncol 2010;28:(15_Suppl):Abstract 1009. Available at:
_view&confID=74&abstractID=47385.
400. Sari E, Guler G, Hayran M, et al. Comparative study of the
immunohistochemical detection of hormone receptor status and HER-2
expression in primary and paired recurrent/metastatic lesions of patients
with breast cancer. Med Oncol 2011;28:57-63. Available at:
.
401. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor
biopsy alter the management of breast cancer patients with distant
metastases? Ann Oncol 2009;20:1499-1504. Available at:
.
402. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status
determined by fluorescence in situ hybridization in primary and
metastatic breast carcinoma. Cancer 2005;103:1763-1769. Available at:
.
403. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary
breast cancers and matched distant metastases. Breast Cancer Res
2007;9. Available at:
404. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast
cancer markers such as estrogen receptor, progesterone receptor, and
human epidermal growth factor receptor 2 are unstable throughout
tumor progression. J Clin Oncol 2012;30:2601-2608. Available at:
.
405. Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor
status between primary and recurrent breast cancer has a prognostic
impact: a single-institution analysis. Ann Oncol 2013;24:101-108.
Available at: .
406. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence
patterns after mastectomy and doxorubicin-based chemotherapy:
implications for postoperative irradiation. J Clin Oncol 2000;18:2817-
2827. Available at: .
407. van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after
treatment for loco-regional recurrence after mastectomy or breast
conserving therapy in two randomised trials (EORTC 10801 and DBCG-
82TM). EORTC Breast Cancer Cooperative Group and the Danish
Breast Cancer Cooperative Group. Eur J Cancer 1999;35:32-38.
Available at: .
408. Cox CE, Furman BT, Kiluk JV, et al. Use of reoperative sentinel
lymph node biopsy in breast cancer patients. J Am Coll Surg
2008;207:57-61. Available at:
.
409. Higgins MJ, Wolff AC. Therapeutic options in the management of
metastatic breast cancer. Oncology (Williston Park) 2008;22:614-623.
Available at: .
410. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report:
Bone health in cancer care. J Natl Compr Canc Netw 2009;7 Suppl 3:1-
1. Available at:
411. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of
Clinical Oncology 2003 update on the role of bisphosphonates and
bone health issues in women with breast cancer. J Clin Oncol
2003;21:4042-4057. Available at:
.
412. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with
zoledronic acid for the treatment of bone metastases in patients with
advanced breast cancer: A randomized, double-blind study. J Clin
Oncol 2010;28:5132-5139. Available at:
.